Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FR0EF
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,714
Award facts
- Contract value 100% obligated
- $19,714.43 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen (dupilumab injection) with a ceiling value of $19,714.43 under a firm fixed-price contract type. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by December 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026.
The SPE2DX contract represents a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. This prime indefinite delivery vehicle encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. AmerisourceBergen serves as a critical federal vendor for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this flexible contract mechanism. The current delivery order for DUPIXENT—a biologic medication used primarily for atopic dermatitis and other immune-mediated conditions—reflects the company's ongoing role in supplying specialized pharmaceutical products for military and federal healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FR0EF?
SPE2DR26FR0EF was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FR0EF worth?
The government has obligated $19,714 on SPE2DR26FR0EF.
Is contract SPE2DR26FR0EF an order under another contract?
Yes. SPE2DR26FR0EF is a delivery order under SPE2DR25D3006, an indefinite delivery contract.
Was contract SPE2DR26FR0EF competed?
The extent of competition for SPE2DR26FR0EF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award